| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/15/2007 | US7217422 Compositions and methods for enhancing corticosteroid delivery |
| 05/15/2007 | US7217409 Suspension stabilizing agents for pharmaceutical aerosols |
| 05/15/2007 | CA2294337C Preparation of pharmaceutical compositions |
| 05/15/2007 | CA2268455C Methods and apparatus for treatment of parkinson's disease |
| 05/15/2007 | CA2255540C Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 05/15/2007 | CA2245558C Affinity labeling libraries and applications thereof |
| 05/15/2007 | CA2215258C Method of making a pressure sensitive skin adhesive sheet material |
| 05/15/2007 | CA2149922C Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| 05/15/2007 | CA2065414C Treatment of autoimmune disease |
| 05/15/2007 | CA2011633C Intercellular adhesion molecule - 2 and its binding ligands |
| 05/10/2007 | WO2007053718A1 Antibodies and immunotoxins that target human glycoprotein nmb |
| 05/10/2007 | WO2007053533A2 Sodium chloride solution for drug reconstitution or dilution |
| 05/10/2007 | WO2007053292A2 Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates |
| 05/10/2007 | WO2007052802A1 Reduced coenzyme q10-containing composition which is stable against oxidation, and method for stabilization of reduced coenzyme q10 |
| 05/10/2007 | WO2007052793A1 Patch |
| 05/10/2007 | WO2007052738A1 Medicinal composition showing improved drug absorbability |
| 05/10/2007 | WO2007052728A1 Method for improvement in transformation efficiency or homologous recombination efficiency in cell by using dna oligomer as carrier for gene delivery, and cell transformed using the method |
| 05/10/2007 | WO2007052629A1 Oligo double-stranded rna and pharmaceutical composition |
| 05/10/2007 | WO2007052592A1 Pharmaceutical preparation having excellent photostability |
| 05/10/2007 | WO2007052357A1 Isosorbide preparation |
| 05/10/2007 | WO2007052076A2 Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases |
| 05/10/2007 | WO2007051923A2 Polyglutamic acids functionalised by histidine derivatives and hydrophobic groups and the uses thereof in particular for therapeutic purposes |
| 05/10/2007 | WO2007051830A2 Composition for the transdermal administration of physiologically active agents |
| 05/10/2007 | WO2007051743A2 Use of a copolymer in the form of a solubiliser for a poorly water-soluble compound |
| 05/10/2007 | WO2007051528A1 Oil-ιn-water emulsions |
| 05/10/2007 | WO2007051476A1 Use of a liquid allergy vaccine formulation for oromucosal administration |
| 05/10/2007 | WO2007051358A1 HYDROXYPROPYL-SULFOBUTYL-β-CYCLODEXTRIN, THE PREPARATION METHOD,THE ANALYTICAL METHOD AND THE PHARMACUTICAL APPLICATION THEREOF |
| 05/10/2007 | WO2007051303A1 MODIFIED siRNA MOLECULES AND USES THEREOF |
| 05/10/2007 | WO2007032993A3 Surfactant systems for delivery of organic compounds |
| 05/10/2007 | WO2007028347A3 Method for the preparation of polymeric conjugates of doxorubicin with ph- controlled release of the drug |
| 05/10/2007 | WO2007016164A3 Cat1 transporters expressed in blood brain barrier cells |
| 05/10/2007 | WO2007016161A3 Oct3 transporters expressed in blood brain barrier cells |
| 05/10/2007 | WO2007002837A3 Methods and compositions for the prevention and treatement of inflammatory disease |
| 05/10/2007 | WO2006129095A3 Sustained release preparations of pro-insulin c-peptide |
| 05/10/2007 | WO2006122828A3 Optimized injection formulation for rna |
| 05/10/2007 | WO2006102395A3 Delivery systems and methods for diagnosing and treating cardiovascular diseases |
| 05/10/2007 | WO2006085336A3 Stabilized anthracycline glycoside pharmaceutical compositions |
| 05/10/2007 | WO2006083961A3 Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders |
| 05/10/2007 | WO2006037090A3 Drug-phosphate conjugates as prodrugs |
| 05/10/2007 | WO2005094884A3 Boron containing nanoparticles targeted to t-cells |
| 05/10/2007 | WO2004110337A3 Cell permeable conjugates of peptides for inhibition of protein kinases |
| 05/10/2007 | WO2004064539A3 Fat substitutes |
| 05/10/2007 | WO2002010431A3 Functional biopolymer modification reagents and uses thereof |
| 05/10/2007 | US20070106066 Cherkasky fusion proteins containing antibody-, antigen- and microtubule-binding regions and immune response-triggering regions |
| 05/10/2007 | US20070105956 Drug containing (2r)-2-propyloctanoic acid as the active ingredient |
| 05/10/2007 | US20070105818 Water solubility, bioavailability, oral administration; unit dosage |
| 05/10/2007 | US20070105815 Biocompatible poly-beta-1-4-N-acetylglucosamine |
| 05/10/2007 | US20070105750 Novel plasma protein affinity tags |
| 05/10/2007 | US20070104770 Methods and Compositions For Topical Wound Treatment |
| 05/10/2007 | US20070104762 Appetizer supplement to suppress age-related decline in capacity and appetite |
| 05/10/2007 | US20070104761 Low radiocarbon nucleotide and amino acid dietary supplements |
| 05/10/2007 | US20070104760 Enteropathy ameliorating composition |
| 05/10/2007 | US20070104759 Sustained release inserts; mixture of thermoplastic polyester, solvent and leuprolide acetate; prostate cancer |
| 05/10/2007 | US20070104757 Latent reactive blood compatible agents |
| 05/10/2007 | US20070104738 Extracellular vesicles from non-pathogenic amoebae useful as vehicle for transferring a molecule of interest to an eukaryotic cell |
| 05/10/2007 | US20070104724 Attaching substances to microorganisms |
| 05/10/2007 | US20070104719 Caspase Activated Prodrugs Therapy |
| 05/10/2007 | US20070104709 Non-naturally occurring ligand for umami taste and sweet taste receptor; enhancing response to artificial flavoring |
| 05/10/2007 | US20070104682 Composition comprising interferon (IFN), buffer, 2-hydroxypropyl-beta-cyclodextrin ("HPBCD"), isotonicity agents and an antioxidant; enhancing cytokine shelf-life at room temperature |
| 05/10/2007 | US20070104658 Preparing spray-dried particles having a tap density of less than about 0.4 g/cm3 and have a hydrophobic amino acid and a therapeutic, prophylactic or diagnostic agent; pulmonary delivery; respiratory disorders |
| 05/10/2007 | US20070104657 Made by creating hollow, spherical drug particles (i.e., progenitor particles) that collapse in the process of particle formation, leading to wrinkled, thin-walled drug particles of very low envelope density; spray drying |
| 05/10/2007 | US20070104656 Matrices Formed of Polymer and Hydrophobic Compounds For Use in Drug Delivery |
| 05/10/2007 | US20070104652 Pharmaceutical spray formulation comprising a hydro fluor alkane and an acylated cyclodextrin |
| 05/10/2007 | US20070104651 comprises a sclerosant liquid, e.g. polidocanol solution, and a gas e.g. O2 or CO2; by inter alia causing a localised inflammatory reaction, favor the elimination of varicose veins and other disorders involving venous malformation |
| 05/10/2007 | US20070104644 Inhibitor imaging agents |
| 05/10/2007 | DE102005053011A1 Use of tetraorganosilicon compound having cell proliferation inhibitory activity, e.g. as an immunstimulator to treat viral-, bacterial- and/or tumor diseases, anemia, arteriosclerosis, arthritis, asthma, autoimmune disease, and cirrhosis |
| 05/10/2007 | CA2852198A1 Aerosol propellants comprising unsaturated fluorocarbons |
| 05/10/2007 | CA2628300A1 Modified sirna molecules and uses thereof |
| 05/10/2007 | CA2628226A1 Use of a liquid allergy vaccine formulation for oromucosal administration |
| 05/10/2007 | CA2628055A1 Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates |
| 05/10/2007 | CA2627890A1 Antibodies and immunotoxins that target human glycoprotein nmb |
| 05/10/2007 | CA2627746A1 Polyglutamic acids functionalised by histidine derivatives and hydrophobic groups and the uses thereof in particular for therapeutic purposes |
| 05/10/2007 | CA2625096A1 Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases |
| 05/10/2007 | CA2620126A1 Food grade antioxidant and flavorant from roasted wheat malt |
| 05/10/2007 | CA2618799A1 Aqueous anaesthetic compositions comprising propofol |
| 05/10/2007 | CA2617598A1 Use of sdf-1 for the treatment and/or prevention of neurological diseases |
| 05/09/2007 | EP1783141A1 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/09/2007 | EP1783137A1 Galactose derivative, drug carrier and medicinal composition |
| 05/09/2007 | EP1782849A2 Three-dimensional stromal tissue |
| 05/09/2007 | EP1782837A2 Hapten-carrier conjugates for use in drug-abuse therapy (nicotine) |
| 05/09/2007 | EP1782836A2 Hapten-carrier conjugates for use in drug-abuse therapy (cocaine) |
| 05/09/2007 | EP1782835A2 Hapten-carrier conjugates for use in drug-abuse therapy |
| 05/09/2007 | EP1782834A2 Oxycodone conjugates with lower abuse potential and extended duration of action |
| 05/09/2007 | EP1782833A2 pH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy |
| 05/09/2007 | EP1782830A1 Preventive and/or remedy for lower urinary tract diseases containing ep4 agonist |
| 05/09/2007 | EP1782829A1 Preventive and/or remedy for hyperkalemia containing ep4 agonist |
| 05/09/2007 | EP1782816A1 Water-based medicinal composition containing azithromycin and method of preparing the same |
| 05/09/2007 | EP1782807A1 Jelly composition |
| 05/09/2007 | EP1782803A1 Coenzyme q10-containing composition |
| 05/09/2007 | EP1782801A1 Eyewash liquid for dry eye therapy |
| 05/09/2007 | EP1782799A2 Transdermal therapeutic system comprising an active analogue of fentanyl |
| 05/09/2007 | EP1782796A1 Carrier for migration into cerebral neuron containing metal colloid particle |
| 05/09/2007 | EP1782794A2 Anhydrous composition containing an acid-acid buffer system |
| 05/09/2007 | EP1781719A1 Use of amphiphilic copolymers as solubilising agents |
| 05/09/2007 | EP1781707A1 Hyaluronic acid butyric esters with a low degree of substitution, procedure for their preparation and use |
| 05/09/2007 | EP1781593A2 Cationic lipids and methods of use |
| 05/09/2007 | EP1781339A1 Compounds of the inventions of guanylyl cyclase c |
| 05/09/2007 | EP1781335A2 Hydrogel polymeric conjugates of a prodrug |
| 05/09/2007 | EP1781334A2 Compositions and methods for activating protein synthesis and deactivating catabolic processes in skeletal muscle |
| 05/09/2007 | EP1781333A2 Compositions and methods for nutrition supplementation |